Opentrons Labworks Inc. has closed a $40 million Series E funding round led by healthcare investor Avego, aiming to expand adoption of its AI-enabled robotic platforms that automate repetitive lab workflows worldwide.
- Raised $40M to expand AI robotics and data tooling for labs
- Robots automate pipetting, sample prep, and experiment workflows
- Over 11,000 units deployed worldwide including top pharma firms
Market signal
Opentrons' successful $40 million Series E funding round highlights growing investor confidence in AI-driven laboratory automation solutions. The market is responding to increasing demand from research institutions and pharmaceutical companies for scalable tools that reduce manual tasks and speed up scientific discovery.
The company’s lineup, featuring the Flex and OT-2 robotic workstations, illustrates a trend towards accessible, configurable benchtop automation. This is enabling more labs globally to integrate robotics for routine lab functions such as DNA extraction, PCR, and protein assays, signaling a shift from manual operations to semi-autonomous lab environments.
Operator impact
For laboratory operators and buyers, Opentrons’ platforms provide options to customize automation based on throughput needs and complexity. The Flex offers expanded capacity with robotic plate handling for end-to-end experiment automation, while the OT-2 addresses entry-level automation requirements with affordable liquid handling.
By adopting these systems, operators can reallocate scientist time from repetitive manual pipetting to higher-value tasks, improving lab productivity and experiment reliability. Integration of AI alongside robotics further supports continuous optimization of workflows, helping labs overcome physical bottlenecks in experimental throughput.
What to watch next
Key developments to monitor include the expansion of AI capabilities within Opentrons’ software that enable autonomous experiment design and iterative improvements. Progress in closed-loop automation combining AI decision-making with robotic execution could accelerate adoption across more life sciences settings.
Additionally, interest from large pharmaceutical companies—already among the early adopters—may drive demand for integrated lab automation ecosystems. How Opentrons expands its partnerships and product integrations to support complex multi-step experimental protocols will be pivotal to its long-term market positioning.